Climb Bio, Inc. CLYM
We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.
We are developing our product candidates for multiple immune-mediated diseases, as summarized in the pipeline figure below.
We acquired the rights to our product candidates through license and asset purchase agreements. We have worldwide rights to develop and commercialize budoprutug for all indications, except for oncology. We have rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan, which we refer to as Greater China.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $46.7M | $14.3M | $15.4M | $26.2M | $23.3M | $8.8M | — |
| SG&A | $21.2M | $16.0M | $24.9M | $18.9M | $12.3M | $2.4M | — |
| Total operating expenses | $67.9M | $82.0M | $40.3M | $45.1M | $35.7M | $20.9M | — |
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M | -$20.9M | — |
| Pre-tax income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M | -$20.7M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M | -$20.7M | — |
| EPS, basic | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | — | — |
| EPS, diluted | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -10.49 | — |
| Shares, diluted (wtd. avg.) | 67.8M | 48.2M | 27.0M | 26.3M | 12.3M | 2.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $35.7M | $87.2M | $93.1M | $43.6M | $46.9M | $20.5M | $21.2M |
| Short-term investments | $65.4M | $63.7M | $13.7M | $80.0M | $89.6M | $0 | — |
| Total current assets | $105.8M | $154.9M | $110.3M | $134.4M | $148.3M | $22.0M | — |
| Property, plant and equipment | $288.0K | $199.0K | — | — | — | — | — |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M | $24.6M | — |
| Accounts payable | $2.3M | $705.0K | $66.0K | $750.0K | $1.4M | $1.1M | — |
| Total current liabilities | $7.0M | $4.9M | $2.8M | $6.1M | $6.0M | $3.1M | — |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M | $3.1M | — |
| Retained earnings | -$289.7M | -$229.9M | -$156.0M | -$120.9M | -$75.6M | -$28.1M | — |
| Total equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M | -$25.0M | -$5.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M | -$14.1M | — |
| Depreciation and amortisation | $97.0K | $0 | — | — | — | — | — |
| Stock-based compensation | $8.1M | $5.6M | $12.8M | $7.0M | $3.7M | $707.0K | — |
| Capital expenditure | $186.0K | $0 | $0 | — | — | — | — |
| Investing cash flow | $2.8M | -$121.1M | $69.0M | $34.4M | -$115.0M | $8.1M | — |
| Financing cash flow | -$21.0K | $130.7M | $841.0K | $0 | $177.2M | $4.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-092546.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Other event Item 8.01
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |